Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2016 1
2017 5
2018 3
2019 7
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Faivre-Finn C, et al. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28642008 Free PMC article. Clinical Trial.
The CONVERT Trial: Interpretation, Journey and Lessons Learnt.
Faivre-Finn C, Falk S, Blackhall F. Faivre-Finn C, et al. Clin Oncol (R Coll Radiol). 2017 Dec;29(12):811-813. doi: 10.1016/j.clon.2017.09.002. Epub 2017 Sep 19. Clin Oncol (R Coll Radiol). 2017. PMID: 28935186 No abstract available.
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C, Falk S, Ashcroft L, Bewley M, Lorigan P, Wilson E, Groom N, Snee M, Fournel P, Cardenal F, Bezjak A, Blackhall F. Faivre-Finn C, et al. BMJ Open. 2016 Jan 20;6(1):e009849. doi: 10.1136/bmjopen-2015-009849. BMJ Open. 2016. PMID: 26792218 Free PMC article. Clinical Trial.
18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial.
Manoharan P, Salem A, Mistry H, Gornall M, Harden S, Julyan P, Locke I, McAleese J, McMenemin R, Mohammed N, Snee M, Woods S, Westwood T, Faivre-Finn C. Manoharan P, et al. J Thorac Oncol. 2019 Jul;14(7):1296-1305. doi: 10.1016/j.jtho.2019.03.023. Epub 2019 Apr 16. J Thorac Oncol. 2019. PMID: 31002954 Free PMC article. Clinical Trial.
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY, Fernández-Gutiérrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F. Tay RY, et al. Ann Oncol. 2019 Jul 1;30(7):1114-1120. doi: 10.1093/annonc/mdz122. Ann Oncol. 2019. PMID: 31020334 Free PMC article. Clinical Trial.
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.
Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farré N, Zwitter M, Lerouge D, Pourel N, Janicot H, Scherpereel A, Tissing-Tan C, Peignaux K, Geets X, Konopa K, Faivre-Finn C. Christodoulou M, et al. J Thorac Oncol. 2019 Jan;14(1):63-71. doi: 10.1016/j.jtho.2018.09.027. Epub 2018 Oct 31. J Thorac Oncol. 2019. PMID: 30391573 Free PMC article. Clinical Trial.
18 results